– Round co-led by Apeiron Investment Group and Catalio Capital Management
– Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies
BOSTON, MA and ROCKVILLE, MD – January 11, 2021 – Sensei Biotherapeutics, …
– SNS-301 demonstrated prolonged partial response and improvement in immune markers in PD-L1 negative disease patient with 43% tumor reduction
– 30+ week stable disease observed in 2 patients
BOSTON, Mass. & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a …
GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the appointment of Anu Hoey as Chief Business Officer, responsible for leading business …
BOSTON & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the completion of a $28.5 million equity financing. The financing was co-led by …
BOSTON & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company …
GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer, responsible for leading clinical and development strategy and operations. Dr. …
Acquisition Advances Sensei’s Core Capabilities in Immunology and Antibody Engineering by Supercharging its ImmunoPhage™ Platform
GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the acquisition of Alvaxa Biosciences, …
Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team
GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Robert …
GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 31st Annual Piper Jaffray Healthcare …
GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating SNS-301 in patients with ASPH‑positive head and neck cancer who …